Leveraging a combination of dedicated and embedded sites under a single partnership, Empathx brings sponsors unparalleled access to known immunocompromised and demographically diverse patients, enabling rapid enrollment, near-perfect retention, and the exceptional data necessary for accelerated approval of novel vaccines and treatments.
Empathx was well-positioned and capable of responding to the growing global need during the COVID-19 pandemic, randomizing 746 participants in a single prevention program.
We continue to be the partner of choice in the post-COVID era.
Our Research Areas
Empathx research sites and physician investigators successfully completed studies in multiple therapeutic subcategories in the Infectious Disease space.
We Are Proud to Have Partnered With
